{Reference Type}: Journal Article
{Title}: Dapagliflozin promotes browning of white adipose tissue through the FGFR1-LKB1-AMPK signaling pathway.
{Author}: Lv Y;Zhao C;Jiang Q;Rong Y;Ma M;Liang L;Li W;Zhang J;Xu N;Wu H;
{Journal}: Mol Biol Rep
{Volume}: 51
{Issue}: 1
{Year}: 2024 Apr 21
{Factor}: 2.742
{DOI}: 10.1007/s11033-024-09540-3
{Abstract}: <B>BACKGROUND: </B>Obesity is associated with a wide variety of metabolic disorders that impose significant burdens on patients and society. The "browning" phenomenon in white adipose tissue (WAT) has emerged as a promising therapeutic strategy to combat metabolic disturbances. However, though the anti-diabetic drug dapagliflozin (DAPA) is thought to promote "browning," the specific mechanism of this was previously unclear.<BR><B>METHODS: </B>In this study, C57BL/6 J male mice were used to establish an obesity model by high-fat diet feeding, and 3T3-L1 cells were used to induce mature adipocytes and to explore the role and mechanism of DAPA in "browning" through a combination of in vitro and in vivo experiments.<BR><B>RESULTS: </B>The results show that DAPA promotes WAT "browning" and improves metabolic disorders. Furthermore, we discovered that DAPA activated "browning" through the fibroblast growth factor receptors 1-liver kinase B1-adenosine monophosphate-activated protein kinase signaling pathway.<BR><B>CONCLUSIONS: </B>These findings provide a rational basis for the use of DAPA in treating obesity by promoting the browning of white adipose tissue.